Anteris Technologies Global Corp. — Capital/Financing Update 2021

May 31, 2021

ASX ANNOUNCEMENT

1 June 2021

CLEANSING NOTICE

Anteris Technologies Ltd (ASX: AVR) ( Anteris or the Company ) has issued 310,386 fully paid ordinary shares ( New Shares ) on 31 May 2021 to various institutional and sophisticated investors at an issue price of $7.50 per New Share, raising approximately $2.3M before issue costs. The funds raised will be utilised for general working capital as well as to undertake research and development related to the Transcatheter Aortic Valve Replacement project.

Details of the securities issued

Class of securities: Fully paid ordinary shares ASX code: AVR Date of the issue: 31 May 2021 Total number of securities issued: 310,386

Anteris gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)[1] (the Corporations Act ) that:

1. the New Shares have been issued without disclosure to investors under Part 6D.2 of the Corporations Act;

2. as at the date of this notice, the Company has complied with:

   • (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   • (b) section 674 of the Corporations Act; and

3. it has been exploring its longer term capital plans, including the potential to list or dual list on another stock exchange. The Company is continuing to explore its options in relation to its ongoing listing and capital plans and will keep ASX informed in compliance with its continuous disclosure obligations; and

4. apart from the matters noted above, as at the date of this notice, there is no other ‘excluded information’ of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

ENDS

---

1. As modified by ASIC Instrument 21-0248 dated 7 April 2021 which extends the period of 5 days referred to in sections 708A(5)(b), 708A(12C)(c) and 708AA(2)(c) of the Corporations Act to 6 days in respect of shares and convertible notes issued by the Company.

Anteris Technologies Ltd Registered Office: Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

==> picture [95 x 51] intentionally omitted <==

Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT[®] tissue technology, paired with DurAVR™’s unique 3D singlepiece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

For more information:

Ms Kyahn Williamson WE Communications E: WE-AUAnterisTech@we-worldwide.com P: +61 401 018 828 www.anteristech.com Twitter: @AnterisTech Facebook: www.facebook.com/AnterisTech

==> picture [95 x 51] intentionally omitted <==

AUI-931374359v1